A multicenter, prospective sibling oocyte study revealed that HyperSperm™ improves the number and quality of embryos in patients undergoing in vitro fertilization

Abstract

Background: Assisted reproductive technologies (ART), including in vitro fertilization (IVF), have transformed the treatment of infertility; however, success rates remain suboptimal. HyperSperm is a novel capacitation technology designed to enhance sperm function by promoting hyperactivation without compromising acrosomal integrity or sperm viability. Previous studies have shown that HyperSperm improves human sperm motility parameters and increases embryo development in mice and humans, as well as implantation rates in mice. The present study aimed to evaluate the clinical utility of HyperSperm in IVF. Methods: A prospective sibling oocyte study was conducted in 41 IVF patients (ClinicalTrials.gov identifier: NCT05680363). Semen samples from each patient were divided and processed using either standard preparation protocols or the HyperSperm protocol. Fertilization outcomes, embryo development, blastocyst formation, embryo quality, and euploidy rates assessed by preimplantation genetic testing for aneuploidy (PGT-A) were compared between conditions. Results: HyperSperm treatment was associated with significantly higher blastocyst development rates compared with standard preparation (55.6% vs. 47.9%, p=0.0038), resulting in a greater number of blastocysts per cycle. Moreover, embryos generated following HyperSperm treatment exhibited improved morphological quality and a higher euploidy rate as determined by PGT-A. Conclusions: HyperSperm improves key developmental outcomes in IVF, increasing blastocyst yield, embryo quality, and chromosomal normality. These findings support the translational potential of HyperSperm as a clinically relevant strategy to enhance early embryo competence and improve IVF efficiency.